Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EffRx Pharmaceuticals has received FDA approval for BINOSTO (alendronate sodium) effervescent tablets for the treatment of osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis.
Subscribe to our email newsletter
The company expects to launch the product in the US in the third quarter of 2012.
BINOSTO is a treatment option for those patients who have difficulty with tablets, the company said.
EffRx chairman and CEO Christer Rosen said BINOSTO is meant for those patients who have difficulty with tablets the proven fracture risk reduction of alendronate in a pleasant tasting and easy-to-swallow buffered solution.